{
    "id": 18311,
    "fullName": "FGFR4 P712T",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR4 P712T lies within the protein kinase domain of the Fgfr4 protein (UniProt.org). P712T confers a gain of function to the Fgfr4 protein, as indicated by increased activation of ERK signaling in cell culture (PMID: 23836671).",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2264,
        "geneSymbol": "FGFR4",
        "terms": [
            "FGFR4",
            "CD334",
            "JTK2",
            "TKF"
        ]
    },
    "variant": "P712T",
    "createDate": "02/19/2016",
    "updateDate": "02/19/2016",
    "referenceTranscriptCoordinates": {
        "id": 164565,
        "transcript": "NM_213647",
        "gDna": "chr5:g.177096722C>A",
        "cDna": "c.2134C>A",
        "protein": "p.P712T",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1389,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) reduced MEK pathway activation and promoted apoptosis of lung cancer cells harboring KRAS G12C and FGFR4 P712T mutations in culture (PMID: 23836671).",
            "molecularProfile": {
                "id": 18651,
                "profileName": "FGFR4 P712T KRAS G12C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LY2874455 resulted in decreased ERK pathway activation and reduced viability of non-small cell lung cancer (NSCLC) cells harboring FGFR4 P712T along with KRAS G12C in culture, and did not effect viability of NSCLC cells lacking FGFR4 activating mutations (PMID: 23836671).",
            "molecularProfile": {
                "id": 18651,
                "profileName": "FGFR4 P712T KRAS G12C"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18650,
            "profileName": "FGFR4 P712T",
            "profileTreatmentApproaches": [
                {
                    "id": 9755,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR4 P712T"
                },
                {
                    "id": 9753,
                    "name": "STAT3 Inhibitor",
                    "profileName": "FGFR4 P712T"
                },
                {
                    "id": 9754,
                    "name": "FGFR4 Inhibitor",
                    "profileName": "FGFR4 P712T"
                }
            ]
        },
        {
            "id": 18651,
            "profileName": "FGFR4 P712T KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 164565,
            "transcript": "NM_213647",
            "gDna": "chr5:g.177096722C>A",
            "cDna": "c.2134C>A",
            "protein": "p.P712T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164567,
            "transcript": "XM_005265838",
            "gDna": "chr5:g.177096722C>A",
            "cDna": "c.2134C>A",
            "protein": "p.P712T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 164566,
            "transcript": "NM_002011",
            "gDna": "chr5:g.177096722C>A",
            "cDna": "c.2134C>A",
            "protein": "p.P712T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}